Ga-68-PSMA PET/CT in treatment-naïve patients with prostate cancer: Which clinical parameters and risk stratification systems best predict PSMA-positive metastases?

Julian M RogaschHannes CashSebastian ZschaeckSefer ElezkurtajWinfried BrennerBernd HammMarcus MakowskiHolger AmthauerChristian FurthAlexander D J Baur

Published in: The Prostate (2018)

Clinical parameters and established risk stratification systems for PCa can predict Ga-68-PSMA PET-positive metastases in treatment-naïve patients. Especially YF and BN may improve identification of patients with the highest probability of metastatic disease detected by Ga-68-PSMA PET/CT.

Keyphrases

pet ct
prostate cancer
positron emission tomography
end stage renal disease
squamous cell carcinoma
small cell lung cancer
ejection fraction
newly diagnosed
chronic kidney disease
combination therapy
patient reported outcomes
replacement therapy